Federal Register / Vol. 87, No. 10 / Friday, January 14, 2022 / Proposed Rules 2383 

There appear to be no legitimate 

sources for 4-OH-DiPT, 5-MeO-AMT, 5- 

MeO-MiPT, 5-MeO-DET, and DiPT as 

marketed drugs and no accepted 

medical use in the United States, but 

DEA notes that these substances are 

available for purchase from legitimate 

suppliers for scientific research. There 

is no evidence of significant diversion of 

4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 

5-MeO-DET, and DiPT from legitimate 

suppliers. 

DEA has identified 31 domestic 

suppliers of one or more of the 

following substances: 4-hydroxy-N,Ndiisopropyltryptamine (4-OH-DiPT), 5- 

methoxy-alpha-methyltryptamine (5- 

MeO-AMT), 5-methoxy-N-methyl-Nisopropyltryptamine (5-MeO-MiPT), 5- 

methoxy-N,N-diethyltryptamine (5- 

MeO-DET), and N,Ndiisopropyltryptamine (DiPT). Thirty 

(30) of the 31 domestic suppliers are not 

registered with DEA to handle 

controlled substances. The one 

registered supplier is already registered 

with DEA and has all security and other 

handling processes in place, resulting in 

minimal impact to this supplier. 

Therefore, the remaining 30 nonregistered domestic suppliers are 

affected. Since the vast majority of DEA 

registrants are small entities or are 

employed by small entities, all 30 

affected suppliers are assumed to be 

small entities. It is impossible to know 

how much 4-hydroxy-N,Ndiisopropyltryptamine (4-OH-DiPT), 5- 

methoxy-alpha-methyltryptamine (5- 

MeO-AMT), 5-methoxy-N-methyl-Nisopropyltryptamine (5-MeO-MiPT), 5- 

methoxy-N,N-diethyltryptamine (5- 

MeO-DET), and N,Ndiisopropyltryptamine (DiPT) are 

distributed by these suppliers. It is 

common for suppliers to have items on 

their catalog while not actually having 

any material level of sales. Based on the 

discussion above, DEA believes any 

quantity of sales from these distributors 

for legitimate purposes is minimal. 

Therefore, these suppliers are expected 

to remove the product from their catalog 

rather than incur the cost of obtaining 

a DEA registration and physical security 

for products with minimal sales. 

Therefore, DEA estimates the cost of this 

rule, in form of lost sales, if any, on the 

affected small entities is minimal. DEA 

welcomes any public comment 

regarding this estimate. 

Because of these facts, this proposed 

rule will not, if promulgated, result in 

a significant economic impact on a 

substantial number of small entities. 

Unfunded Mandates Reform Act of 1995 

On the basis of information contained 

in the ‘‘Regulatory Flexibility Act’’ 

section above, DEA has determined 

pursuant to the Unfunded Mandates 

Reform Act (UMRA) of 1995 (2 U.S.C. 

1501 et seq.) that this proposed action 

would not result in any Federal 

mandate that may result ‘‘in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $100,000,000 or more 

(adjusted annually for inflation) in any 

1 year . . . .’’ Therefore, neither a Small 

Government Agency Plan nor any other 

action is required under UMRA of 1995. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, DEA 

proposes to amend 21 CFR part 1308 as 

follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b), unless otherwise noted. 

■ 2. In § 1308.11, as proposed to be 

amended at 86 FR 16553 (March 30, 

2021), 86 FR 37719 (July 16, 2021), and 

86 FR 69187 (December 7, 2021), add 

paragraphs (d)(101) through (105) to 

read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(101) 4-hydroxy-N,Ndiisopropyltryptamine (other names: 4- 

OH-DiPT; 3-(2- 

(diisopropylamino)ethyl)-1H-indol-4-ol) 

7516. 

(102) 5-methoxy-alphamethyltryptamine (Other names: 5- 

MeO-AMT; 1-(5-methoxy-1H-indol-3- 

yl)propan-2-amine) 7506. 

(103) 5-methoxy-N-methyl-Nisopropyltryptamine (Other names: 5- 

MeO-MiPT; N-(2-(5-methoxy-1H-indol3-yl)ethyl)-N-methylpropan-2-amine) 

7512. 

(104) 5-methoxy-N,Ndiethyltryptamine (Other names: 5- 

MeO-DET; N,N-diethyl-2-(5-methoxy1H-indol-3-yl)ethanamine) 7525. 

(105) N,N-diisopropyltryptamine 

(Other names: DiPT; N-(2-(1H-indol-3- 

yl)ethyl)-N-isopropylpropan-2-amine) 

7522. 

* * * * * 

Anne Milgram, 

Administrator. 

[FR Doc. 2022–00713 Filed 1–13–22; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF THE INTERIOR 

National Indian Gaming Commission 

25 CFR Part 537 

RIN 3141–AA58 

Background Investigations for Persons 

or Entities With a Financial Interest in 

or Having a Management 

Responsibility for a Management 

Contract; Correction 

AGENCY: National Indian Gaming 

Commission, Department of the Interior. 

ACTION: Proposed rule; correction. 

SUMMARY: This document corrects the 

preamble to a proposed rule published 

in the Federal Register of December 2, 

2021, regarding Background 

Investigations for Persons or Entities 

with a Financial Interest in or Having a 

Management Responsibility for a 

Management Contract. The document 

contained incorrect dates for submitting 

comments. This correction clarifies that 

comments are due January 31, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Michael Hoenig, 202–632–7003. 

SUPPLEMENTARY INFORMATION: 

Correction 

In the Federal Register of December 2, 

2021, in proposed rule FR Doc. 2021– 

25844, on page 68446, in the second 

column, change the DATES caption to 

read: 

DATES: Written comments on this 

proposed rule must be received on or 

before January 31, 2022. 

Dated: January 6, 2022. 

Michael Hoenig, 

General Counsel. 

[FR Doc. 2022–00631 Filed 1–13–22; 8:45 am] 

BILLING CODE 7565–01–P 

DEPARTMENT OF THE INTERIOR 

National Indian Gaming Commission 

25 CFR Part 537 

RIN 3141–AA77 

Fees; Correction 

AGENCY: National Indian Gaming 

Commission, Department of the Interior. 

ACTION: Proposed rule; correction. 

SUMMARY: This document corrects the 

preamble to a proposed rule published 

in the Federal Register of December 2, 

2021, regarding Fees. The document 

contained incorrect dates for submitting 

comments. This correction clarifies that 

comments are due January 31, 2022. 


lotter on DSK11XQN23PROD with PROPOSALS1